Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Total Non-Current Liabilities (2021 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Total Non-Current Liabilities for 5 consecutive years, with $14.5 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 17.69% to $14.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.5 million through Dec 2025, down 17.69% year-over-year, with the annual reading at $14.5 million for FY2025, 17.69% down from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $14.5 million at Whitehawk Therapeutics, up from $9.8 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $27.2 million in Q4 2023, with the low at $8.8 million in Q2 2025.
  • Average Total Non-Current Liabilities over 5 years is $16.4 million, with a median of $16.4 million recorded in 2024.
  • Peak annual rise in Total Non-Current Liabilities hit 17.69% in 2025, while the deepest fall reached 40.08% in 2025.
  • Over 5 years, Total Non-Current Liabilities stood at $21.5 million in 2021, then fell by 7.94% to $19.8 million in 2022, then soared by 37.54% to $27.2 million in 2023, then plummeted by 35.22% to $17.6 million in 2024, then fell by 17.69% to $14.5 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $14.5 million, $9.8 million, and $8.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.